Angiogenic markers in breath condensate identify non-small cell lung cancer

Lung Cancer

Volumn 68, Issue 2, 2010, Pages 177-184

  Gessner, C ^a   Rechner, B ^a   Hammerschmidt, S ^a   Kuhn, H ^a   Hoheisel, G ^a   Sack, U ^a   Ruschpler, P ^a   Wirtz, H ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Angiogenic markers; Angiogenin; BFGF; Biomarkers; Exhaled breath condensate; Lung cancer; Multiplex bead based immunoassay; VEGF

Indexed keywords

ANGIOGENIN; BASIC FIBROBLAST GROWTH FACTOR; INTERLEUKIN 8; PLATINUM COMPLEX; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; BREATH ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; EARLY DIAGNOSIS; EXPIRED AIR; FEMALE; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR REGRESSION;

AGED; BREATH TESTS; CARCINOMA, NON-SMALL-CELL LUNG; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RIBONUCLEASE, PANCREATIC; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950458157     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.06.010     Document Type: Article

References (33)

1. Hirsch F.R., Merrick D.T., Franklin W.A. Role of biomarkers for early detection of lung cancer and chemoprevention. Eur Respir J 2002, 19:1151-1158.
2. Pastorino U. Early detection of lung cancer. Respiration 2006, 73:5-13.
3. Ravenel J.G., Costello P., Silvestri G.A. Screening for lung cancer. AJR Am J Roentgenol 2008, 190:755-761.
4. Conrad D.H., Goyette J., Thomas P.S. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med 2008, 23(SUPP1. 1):78-84.
5. Ahrendt S.A., Hu Y., Buta M., McDermott M.P., Benoit N., Yang S.C., et al. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst 2003, 95:961-970.
6. Xu H.J., Quinlan D.C., Davidson A.G., Hu S.X., Summers C.L., Li J., et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 1994, 86:695-699.
7. Kuhn H., Hammerschmidt S., Wirtz H. Targeting tumorangiogenesis in lung cancer by suppression of VEGF and its receptor-results from clinical trials and novel experimental approaches. Curr Med Chem 2007, 14:3157-3165.
8. Folkman J. Is angiogenesis an organizing principle in biology and medicine?. J Pediatr Surg 2007, 42:1-11.
9. Herbst R.S., Onn A., Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005, 23:3243-3256.
10. Fontanini G., Vignati S., Boldrini L., Chine S., Silvestri V., Lucchi M., et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997, 3:861-865.
11. Fontanini G., Faviana P., Lucchi M., Boldrini L., Mussi A., Camacci T., et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002, 86:558-563.
12. Han H., Silverman J.F., Santucci T.S., Macherey R.S., d'Amato T.A., Tung M.Y., et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001, 8:72-79.
13. Iwasaki A., Kuwahara M., Yoshinaga Y., Shirakusa T. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg 2004, 25:443-448.
14. Chan H.P., Lewis C., Thomas P.S. Exhaled breath analysis: novel approach for early detection of lung cancer. Lung Cancer 2008.
15. Gessner C., Kuhn H., Toepfer K., Hammerschmidt S., Schauer J., Wirtz H. Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients. Lung Cancer 2004, 43:215-222.
16. Gessner C., Scheibe R., Wotzel M., Hammerschmidt S., Kuhn H., Engelmann L., et al. Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir Med 2005, 99:1229-1240.
17. Sack U., Scheibe R., Wotzel M., Hammerschmidt S., Kuhn H., Emmrich F., et al. Multiplex analysis of cytokines in exhaled breath condensate. Cytometry A 2006, 69:169-172.
18. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
19. Burge S., Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur Respir J, Suppl. 2003, 41:46s-53s.
20. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001, 163:1256-1276.
21. Gessner C., Kuhn H., Seyfarth H.J., Pankau H., Winkler J., Schauer J., et al. Factors influencing breath condensate volume. Pneumologie 2001, 55:414-419.
22. Huszar E., Vass G., Vizi E., Csoma Z., Barat E., Molnar-Vilagos G., et al. Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma. Eur Respir J 2002, 20:1393-1398.
23. Effros R.M., Hoagland K.W., Bosbous M., Castillo D., Foss B., Dunning M., et al. Dilution of respiratory solutes in exhaled condensates. Am J Respir Crit Care Med 2002, 165:663-669.
24. Goodwin M., Gleeson F.V. The pitfalls of lung cancer screening. Cancer Imaging 2004, 4:52-57.
25. Gomez M., Silvestri G.A. Lung cancer screening. Am J Med Sci 2008, 335:46-50.
26. Carpagnano G.E., Resta O., Foschino-Barbaro M.P., Gramiccioni E., Carpagnano F. Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer. Int J Biol Markers 2002, 17:141-145.
27. Bucchioni E., Kharitonov S.A., Allegra L., Barnes P.J. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med 2003, 97:1299-1302.
28. Carpagnano G.E., Foschino-Barbaro M.P., Resta O., Gramiccioni E., Carpagnano F. Endothelin-1 is increased in the breath condensate of patients with non-small-cell lung cancer. Oncology 2004, 66:180-184.
29. Bacakoglu F., Atasever A., Ozhan M.H., Gurgun C., Ozkilic H., Guzelant A. Plasma and bronchoalveolar lavage fluid levels of endothelin-1 in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Respiration 2003, 70:594-599.
30. Carpagnano G.E., Foschino-Barbaro M.P., Mule G., Resta O., Tommasi S., Mangia A., et al. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. Am J Respir Crit Care Med 2005, 172:738-744.
31. Ohta Y., Ohta N., Tamura M., Wu J., Tsunezuka Y., Oda M., et al. Vascular endothelial growth factor expression in airways of patients with lung cancer: a possible diagnostic tool of responsive angiogenic status on the host side. Chest 2002, 121:1624-1627.
32. Dalaveris E., Kerenidi T., Katsabeki-Katsafli A., Kiropoulos T., Tanou K., Gourgoulianis K.I., et al. VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer 2008.
33. Carpagnano G.E., Spanevello A., Curci C., Salerno F., Palladino G.P., Resta O., et al. IL-2, TNF-alpha, and leptin: local versus systemic concentrations in NSCLC patients. Oncol Res 2007, 16:375-381.